345 related articles for article (PubMed ID: 32671504)
1. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
[TBL] [Abstract][Full Text] [Related]
2. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).
Economopoulou P; Anastasiou M; Papaxoinis G; Spathas N; Spathis A; Oikonomopoulos N; Kotsantis I; Tsavaris O; Gkotzamanidou M; Gavrielatou N; Vagia E; Kyrodimos E; Gagari E; Giotakis E; Delides A; Psyrri A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466719
[No Abstract] [Full Text] [Related]
6. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Vienne A; Collet L; Chevalier T; Borel C; Tardy M; Huguet F; Richard S; Salas S; Saada-Bouzid E; Fayette J; Daste A
BMC Cancer; 2023 Jul; 23(1):663. PubMed ID: 37452287
[TBL] [Abstract][Full Text] [Related]
7. Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
Park JC; Durbeck J; Clark JR; Faden DL
Oral Oncol; 2020 Dec; 111():105024. PubMed ID: 33065374
[TBL] [Abstract][Full Text] [Related]
8. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma.
Karabajakian A; Garrivier T; Crozes C; Gadot N; Blay JY; Bérard F; Céruse P; Zrounba P; Saintigny P; Mastier C; Fayette J
Oncotarget; 2020 May; 11(18):1618-1628. PubMed ID: 32405337
[No Abstract] [Full Text] [Related]
10. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
Dang S; Zhang S; Zhao J; Li X; Li W
Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
[TBL] [Abstract][Full Text] [Related]
13. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
Liu J; Wu Q; Wu S; Xie X
Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
[TBL] [Abstract][Full Text] [Related]
14. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
17. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
[TBL] [Abstract][Full Text] [Related]
18. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
[TBL] [Abstract][Full Text] [Related]
20. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis.
Lien MY; Hwang TZ; Wang CC; Hsieh CY; Yang CC; Wang CC; Lien CF; Shih YC; Yeh SA; Hsieh MC
Target Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 38041732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]